Welcome to our dedicated page for Polypid Ltd. news (Ticker: PYPD), a resource for investors and traders seeking the latest updates and insights on Polypid Ltd. stock.
PolyPid Ltd. (Nasdaq: PYPD) is publicly described as a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, prolonged-release therapeutics. News about PolyPid often centers on the development and regulatory progress of its lead product candidate, D-PLEX100, and on milestones related to its proprietary PLEX (Polymer-Lipid Encapsulation matriX) drug delivery technology.
Investors and observers following PYPD news will find updates on clinical trial results, particularly from the Phase 3 SHIELD II trial of D-PLEX100 in abdominal colorectal surgeries. Company press releases report that this trial met its primary and key secondary endpoints and demonstrated reductions in surgical site infections and related outcomes when D-PLEX100 was added to standard of care.
Regulatory developments are another major theme in PolyPid’s news flow. The company has announced that D-PLEX100 received Breakthrough Therapy designation from the U.S. Food and Drug Administration and has reported positive pre-NDA meeting minutes supporting a New Drug Application submission. News items also describe the FDA’s agreement to a rolling NDA review, which PolyPid highlights as an important step in its regulatory strategy.
Corporate and operational updates appear regularly, including GMP inspection outcomes for the company’s manufacturing facility by the Israeli Ministry of Health, which PolyPid states support its readiness for potential commercial production. Additional news covers participation in medical and investor conferences, board and management changes such as the appointment of a new chairman of the board, and financial results reported via quarterly updates.
For readers tracking PYPD, this news stream provides insight into PolyPid’s clinical progress, regulatory interactions, manufacturing readiness and capital markets activity, all framed around its goal of improving surgical outcomes with prolonged-release therapeutics.
PolyPid announced positive developments for its SHIELD II Phase 3 trial of D-PLEX₁₀₀, designed to prevent surgical site infections in abdominal colorectal surgery. The Data Safety Monitoring Board (DSMB) recommended continuing enrollment to 800 patients, with 630 patients already enrolled. Trial completion is expected in Q1 2025 with top-line results in Q2 2025.
The company also secured a private placement financing of $14.5 million at $3.22 per share, with additional warrants that could provide up to $27 million in gross proceeds. The financing extends PolyPid's cash runway into Q3 2025, beyond the expected trial results. Upon positive Phase 3 data, the company plans to submit a New Drug Application under previously granted Fast Track and Breakthrough Therapy designations.
PolyPid (NASDAQ: PYPD) has announced a research and development collaboration with ImmunoGenesis to enhance cancer immunotherapy treatments. The partnership combines PolyPid's PLEX Technology, which enables controlled and prolonged intratumoral drug delivery, with ImmunoGenesis' STING agonist drug candidate to potentially improve solid tumor treatments. The collaboration specifically aims to address the challenge of rapid clearance of STING agonists during intratumoral administration, which currently limits their effectiveness in the tumor microenvironment.
PolyPid has received notification from Nasdaq of non-compliance with minimum stockholders' equity requirement, as it failed to maintain the required $2.5 million threshold, reporting approximately $2.158 million as of September 30, 2024. The company has until January 9, 2025, to submit a compliance plan, with potential extension up to 180 days if accepted. Trading continues under 'PYPD'. The company anticipates results from SHIELD II Phase 3 trial in December 2024, with potential additional funding of $18.5 million from January PIPE and $6.1 million from August PIPE warrants, contingent on positive trial outcomes.
PolyPid provided updates on its SHIELD II Phase 3 trial of D-PLEX100 for preventing abdominal colorectal surgical site infections. Over 540 patients are enrolled, with the last patient required for the planned unblinded interim analysis now completed. The analysis, expected this quarter, will determine trial continuation or conclusion. Trial enrollment completion of up to 630 patients is expected in December 2024, with top-line results in Q1 2025.
Financial results show R&D expenses of $6.0 million in Q3 2024, up from $3.8 million in Q3 2023. Net loss was $7.8 million ($1.22 per share) compared to $5.6 million ($3.40 per share) in Q3 2023. Cash position stands at $9.5 million, expected to fund operations into Q1 2025.
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in the Craig-Hallum 15th Annual Alpha Select Conference. The event will take place on November 19, 2024, in New York, NY. Company management will be available for investor meetings during the conference. Interested investors are advised to contact conference representatives directly to schedule meetings.
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has scheduled its third quarter 2024 financial results announcement for November 13, 2024, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss results and provide business updates. Interested parties can register for the call through the provided link, with registration recommended at least 5 minutes before the start time. For those not planning to ask questions, the company suggests following via webcast.
PolyPid (Nasdaq: PYPD) announced the publication of results from its Phase 3 SHIELD I trial of D-PLEX₁₀₀ in the International Journal of Surgery. The study, one of the largest Phase 3 trials in surgical site infection (SSI) prevention in colorectal resection in over a decade, did not meet its primary endpoint. However, pre-specified and post-hoc analyses suggested D-PLEX100 may benefit patients with increased SSI risk, particularly those with lengthy incisions.
Key findings include:
- 23% event reduction in the D-PLEX100 arm (not statistically significant)
- 54% reduction in primary outcome events for incisions >20 cm (statistically significant)
- 54.6% reduction in incisional SSI for incisions >20 cm
- No safety concerns raised
The ongoing SHIELD II study focuses on patients with large surgical incisions, with top-line results expected in Q1 2025.
PolyPid (Nasdaq: PYPD) has announced the enrollment of the last patient required for the planned unblinded interim analysis in its ongoing SHIELD II Phase 3 trial for D-PLEX100. This trial aims to prevent surgical site infections in patients undergoing abdominal colorectal surgery with large incisions. The unblinded interim analysis will be conducted in the current quarter, following the 30-day follow-up assessment for the last patient.
Key points:
- Approximately 430 subjects enrolled to date
- The trial is nearly three-quarters enrolled to full planned enrollment (up to 630 subjects)
- Top-line results anticipated in Q1 2025
- Potential for additional funding of $18.5 million from January PIPE and $6.1 million from August PIPE, depending on interim analysis results
- If all warrants are exercised, the company could be funded into 2026
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in three upcoming investor conferences:
- H.C. Wainwright 26th Annual Global Investment Conference: On-demand presentation available from September 9, 2024, at 7:00 AM ET.
- Lytham Partners Fall 2024 Investor Conference: On-demand fireside chat available from October 1, 2024, for 90 days.
- Sidoti & Company Micro-Cap Virtual Conference: Scheduled for November 13-14, 2024.
The PolyPid management team will be available for one-on-one investor meetings during these events. Interested investors should contact the respective conference organizers directly to arrange meetings.
PolyPid (Nasdaq: PYPD) provided a corporate update and reported Q2 2024 financial results. Key highlights include:
- SHIELD II Phase 3 trial of D-PLEX100 has enrolled approximately 320 patients, with an unblinded interim analysis expected in Q4 2024 and top-line results in Q1 2025.
- Successful financing of up to $14 million, extending cash runway into Q2 2025.
- Q2 2024 financial results: R&D expenses $4.8M, G&A expenses $1.1M, net loss $6.3M ($1.25 per share).
- Cash and equivalents of $9.3M as of June 30, 2024, not including $8.1M from recent PIPE financing.